Marex Group’s Arcus Biosciences RCUS Stock Holding History

Marex Group’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,000	Closed	-$163K	–	1111
2025 Q3	$163K	Sell	12,000 -5,000	-29%	-$52K	﹤0.01%	743
2025 Q2	$138K	Sell	17,000 -12,000	-41%	-$102K	﹤0.01%	545
2025 Q1	$228K	Buy	29,000 +15,000	+107%	+$174K	﹤0.01%	549
2024 Q4	$208K	Hold	14,000	–	–	﹤0.01%	539
2024 Q3	$214K	Buy	14,000 +500	+4%	+$7.88K	﹤0.01%	465
2024 Q2	$206K	Hold	13,500	–	–	0.01%	505
2024 Q1	$255K	Buy	+13,500	New	+$233K	0.01%	350

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Marex Group's RCUS Position: Q4 2025 in Review

Marex Group sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 12,000 shares — an estimated $163K sold.

Marex Group first reported a position in RCUS in Q1 2024 and held it in 7 quarters. The position peaked at $255K in Q1 2024. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

Marex Group reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
Marex Group sold 12,000 Arcus Biosciences shares in Q4 2025, an estimated $163K.
Marex Group first reported a position in Arcus Biosciences in Q1 2024 and held it in 7 quarters.
Marex Group's Arcus Biosciences position peaked at $255K in Q1 2024.
209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Marex Group's 13F filing for Q4 2025, filed 12 Feb 2026.